Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02928198
Other study ID # NL50172.018.14
Secondary ID
Status Active, not recruiting
Phase N/A
First received September 9, 2016
Last updated January 15, 2018
Start date June 2016
Est. completion date March 2020

Study information

Verified date January 2018
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Bifurcation ABSORB OCT Trial is a prospective, randomized (1:1) evaluation of the efficacy and performance of single ABSORB everolimus eluting bioresorbable vascular scaffold provisional strategy in the treatment of (a) coronary bifurcation lesion(s) in consecutive subjects with and without fenestration towards the side branch.

Patients included in this study will be divided into three different cohorts:

- Cohort A (patient 1-20): Angiographic FU with OCT at 12 months.

- Cohort B (patient 21-40): Angiographic FU with OCT at 24 months.

- Cohort C (patient 41-60): Angiographic FU with OCT at 36 months.

All patients will also have telephone FU at 30 days, 12, 24 and 36 months.

Inclusion of patients in the BISORB OCT trial stopped in November 2016 after safety concerns of the ABSORB BVS were reported. BISORB OCT included 3 patients, which were all included in the Academic Medical Center


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 3
Est. completion date March 2020
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject has a bifurcation lesion involving a side-branch larger than 2 mm and having main branch involvement (Medina 0,0,1 lesions are excluded).

- Subject must agree to undergo all clinical investigation plan-required follow-up visits and to undergo follow-up angiography and optical coherence tomography.

- Subject is able to verbally confirm understanding and he/she or his/her legally authorized representative provides written informed consent prior to any Clinical Investigation related procedure,as approved by the appropriate Ethics Committee.

Exclusion Criteria:

- Subject is younger than 18 years of age

- Subject is presenting with a STEMI

- Subject has a true bifurcation lesion where a priori two scaffold/stent strategy is planned.

- Subject has known hypersensitivity or contraindication to contrast, aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel, prasugrel and ticagrelor, inclusive), everolimus, poly (L-lactide), poly (DL-lactide), cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.

- Known renal insufficiency (eg. estimated Glomerular Filtration Rate (eGFR) <60mL/min/1.73m2 or serum creatinine level of >2.5mg/dL or subject on dialysis)

- Subject with a limited life expectancy less than one year.

- Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or subject unable to read or write.

Study Design


Intervention

Device:
ABSORB BVS


Locations

Country Name City State
Netherlands Academic Medical Center Amsterdam

Sponsors (3)

Lead Sponsor Collaborator
J.J. Wykrzykowska Abbott Vascular, St. Jude Medical

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Quantitative Coronary Angiography (QCA) derived parameters - All cohorts Proximal 5mm side branch % diameter stenosis (DS) postnitrate Baseline
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A Proximal 5mm side branch % diameter stenosis (DS) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B Proximal 5mm side branch % diameter stenosis (DS) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C Proximal 5mm side branch % diameter stenosis (DS) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A In-segment Late Loss (LL) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B In-segment Late Loss (LL) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C In-segment Late Loss (LL) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A Proximal Late Loss (LL) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B Proximal Late Loss (LL) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C Proximal Late Loss (LL) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A Distal Late Loss (LL) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B Distal Late Loss (LL) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C Distal Late Loss (LL) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - All cohorts In-scaffold/in-stent, in-segment, proximal and distal Minimal Lumen Diameter (MLD) postnitrate Baseline
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A In-scaffold/in-stent, in-segment, proximal and distal Minimal Lumen Diameter (MLD) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B In-scaffold/in-stent, in-segment, proximal and distal Minimal Lumen Diameter (MLD) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C In-scaffold/in-stent, in-segment, proximal and distal Minimal Lumen Diameter (MLD) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - All cohorts In-scaffold/in-stent, in-segment, proximal and distal % diameter stenosis (DS) postnitrate Baseline
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A In-scaffold/in-stent, in-segment, proximal and distal % diameter stenosis (DS) postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B In-scaffold/in-stent, in-segment, proximal and distal % diameter stenosis (DS) postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C In-scaffold/in-stent, in-segment, proximal and distal % diameter stenosis (DS) postnitrate 36 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort A In-scaffold/in-stent, in-segment, proximal and distal angiographic binary restenosis rate postnitrate 12 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort B In-scaffold/in-stent, in-segment, proximal and distal angiographic binary restenosis rate postnitrate 24 months
Other Quantitative Coronary Angiography (QCA) derived parameters - Cohort C In-scaffold/in-stent, in-segment, proximal and distal angiographic binary restenosis rate postnitrate 36 months
Primary Number and appearance of jailed side branch struts, as assessed with three-dimensional OCT - Cohort A 3D reconstruction assessment is done visually and the number of strut free compartments are categorized as follows: Non-jailed side branch or jailed side branch. Non-jailed side branch is defined as either no strut over the sidebranch is present or 1 of the BVS struts is present over the side branch but does not compartmentalize the side branch. Jailed side branch is defined as the BVS struts separate the side branch ostium into n compartments. The distribution of the struts creates different patterns of compartments: V, T, H, double V, double T, and double H. 12 months
Secondary Number and appearance of jailed side branch struts, as assessed with three-dimensional OCT - All cohorts 3D reconstruction assessment is done visually and the number of strut free compartments are categorized as follows: Non-jailed side branch or jailed side branch. Non-jailed side branch is defined as either no strut over the sidebranch is present or 1 of the BVS struts is present over the side branch but does not compartmentalize the side branch. Jailed side branch is defined as the BVS struts separate the side branch ostium into n compartments. The distribution of the struts creates different patterns of compartments: V, T, H, double V, double T, and double H. Baseline
Secondary Number and appearance of jailed side branch struts, as assessed with three-dimensional OCT - Cohort B 3D reconstruction assessment is done visually and the number of strut free compartments are categorized as follows: Non-jailed side branch or jailed side branch. Non-jailed side branch is defined as either no strut over the sidebranch is present or 1 of the BVS struts is present over the side branch but does not compartmentalize the side branch. Jailed side branch is defined as the BVS struts separate the side branch ostium into n compartments. The distribution of the struts creates different patterns of compartments: V, T, H, double V, double T, and double H. 24 months
Secondary Number and appearance of jailed side branch struts, as assessed with three-dimensional OCT - Cohort C 3D reconstruction assessment is done visually and the number of strut free compartments are categorized as follows: Non-jailed side branch or jailed side branch. Non-jailed side branch is defined as either no strut over the sidebranch is present or 1 of the BVS struts is present over the side branch but does not compartmentalize the side branch. Jailed side branch is defined as the BVS struts separate the side branch ostium into n compartments. The distribution of the struts creates different patterns of compartments: V, T, H, double V, double T, and double H. 36 months
Secondary Incomplete strut apposition in the bifurcation region - All cohorts Present when, in case of an ABSORB BVS, the abluminal surface of the polymeric strut (black box) is separated from the vessel wall by flush, between 0.5mm proximal and 0.5mm distal of the side branch. Baseline
Secondary Incomplete strut apposition in the bifurcation region - Cohort A Present when, in case of an ABSORB BVS, the abluminal surface of the polymeric strut (black box) is separated from the vessel wall by flush, between 0.5mm proximal and 0.5mm distal of the side branch. 12 months
Secondary Incomplete strut apposition in the bifurcation region - Cohort B Present when, in case of an ABSORB BVS, the abluminal surface of the polymeric strut (black box) is separated from the vessel wall by flush, between 0.5mm proximal and 0.5mm distal of the side branch. 24 months
Secondary Incomplete strut apposition in the bifurcation region - Cohort C Present when, in case of an ABSORB BVS, the abluminal surface of the polymeric strut (black box) is separated from the vessel wall by flush, between 0.5mm proximal and 0.5mm distal of the side branch. 36 months
Secondary Number of embedded and protruded ABSORB BVS struts per region - All cohorts Embedded struts are defined as present when more than one-half thickness of the strut was impacted into the vessel wall. Baseline
Secondary Number of embedded and protruded ABSORB BVS struts per region - Cohort A Embedded struts are defined as present when more than one-half thickness of the strut was impacted into the vessel wall. 12 months
Secondary Number of embedded and protruded ABSORB BVS struts per region - Cohort B Embedded struts are defined as present when more than one-half thickness of the strut was impacted into the vessel wall. 24 months
Secondary Number of embedded and protruded ABSORB BVS struts per region - Cohort C Embedded struts are defined as present when more than one-half thickness of the strut was impacted into the vessel wall. 36 months
Secondary Incomplete strut coverage in the bifurcation region - Cohort A Absence of strut coverage at the side-branch ostium is defined when one of the strut corners preserved a right angle shape without signs of neointimal tissue, between 0.5mm proximal and 0.5mm distal of the side branch. 12 months
Secondary Incomplete strut coverage in the bifurcation region - Cohort B Absence of strut coverage at the side-branch ostium is defined when one of the strut corners preserved a right angle shape without signs of neointimal tissue, between 0.5mm proximal and 0.5mm distal of the side branch. 24 months
Secondary Incomplete strut coverage in the bifurcation region - Cohort C Absence of strut coverage at the side-branch ostium is defined when one of the strut corners preserved a right angle shape without signs of neointimal tissue, between 0.5mm proximal and 0.5mm distal of the side branch. 36 months
Secondary The number of non-apposed side branch (NASB) struts - All cohorts Non-apposed side branch struts are defined as struts overlying the ostium of a sidebranch, post-scaffold deployment and at follow up. Baseline
Secondary The number of non-apposed side branch (NASB) struts - Cohort A Non-apposed side branch struts are defined as struts overlying the ostium of a sidebranch, post-scaffold deployment and at follow up. 12 months
Secondary The number of non-apposed side branch (NASB) struts - Cohort B Non-apposed side branch struts are defined as struts overlying the ostium of a sidebranch, post-scaffold deployment and at follow up. 24 months
Secondary The number of non-apposed side branch (NASB) struts - Cohort C Non-apposed side branch struts are defined as struts overlying the ostium of a sidebranch, post-scaffold deployment and at follow up. 36 months
Secondary Tissue in-between non-apposed side branch (NASB) struts - Cohort A Tissue in-between NASB struts is defined as any tissue between two NASB ABSORB struts more than two times the polymer thickness. 12 months
Secondary Tissue in-between non-apposed side branch (NASB) struts - Cohort B Tissue in-between NASB struts is defined as any tissue between two NASB ABSORB struts more than two times the polymer thickness. 24 months
Secondary Tissue in-between non-apposed side branch (NASB) struts - Cohort C Tissue in-between NASB struts is defined as any tissue between two NASB ABSORB struts more than two times the polymer thickness. 36 months
Secondary Mean/Minimal Lumen diameter/area - All cohorts Lumen diameter and lumen area are measured at the (neo-)intima layer of the vessel wall, both pre- and post-scaffold deployment and at follow up. At baseline this is usually outside the scaffold diameter/area and at follow up into the scaffold diameter/area Baseline
Secondary Mean/Minimal Lumen diameter/area - Cohort A Lumen diameter and lumen area are measured at the (neo-)intima layer of the vessel wall, both pre- and post-scaffold deployment and at follow up. At baseline this is usually outside the scaffold diameter/area and at follow up into the scaffold diameter/area 12 months
Secondary Mean/Minimal Lumen diameter/area - Cohort B Lumen diameter and lumen area are measured at the (neo-)intima layer of the vessel wall, both pre- and post-scaffold deployment and at follow up. At baseline this is usually outside the scaffold diameter/area and at follow up into the scaffold diameter/area 24 months
Secondary Mean/Minimal Lumen diameter/area - Cohort C Lumen diameter and lumen area are measured at the (neo-)intima layer of the vessel wall, both pre- and post-scaffold deployment and at follow up. At baseline this is usually outside the scaffold diameter/area and at follow up into the scaffold diameter/area 36 months
Secondary Mean/Minimal Scaffold diameter/area - All cohorts Scaffold diameter and scaffold area are measured at the abluminal border of the polymeric struts (black boxes), both post-scaffold deployment and at follow up. Baseline
Secondary Mean/Minimal Scaffold diameter/area - Cohort A Scaffold diameter and scaffold area are measured at the abluminal border of the polymeric struts (black boxes), both post-scaffold deployment and at follow up. 12 months
Secondary Mean/Minimal Scaffold diameter/area - Cohort B Scaffold diameter and scaffold area are measured at the abluminal border of the polymeric struts (black boxes), both post-scaffold deployment and at follow up. 24 months
Secondary Mean/Minimal Scaffold diameter/area - Cohort C Scaffold diameter and scaffold area are measured at the abluminal border of the polymeric struts (black boxes), both post-scaffold deployment and at follow up. 36 months
Secondary Neointima thickness - Cohort A Neointima thickness of the ABSORB BVS is measured from the endoluminal border of the black box to the lumen contour. 12 months
Secondary Neointima thickness - Cohort B Neointima thickness of the ABSORB BVS is measured from the endoluminal border of the black box to the lumen contour. 24 months
Secondary Neointima thickness - Cohort C Neointima thickness of the ABSORB BVS is measured from the endoluminal border of the black box to the lumen contour. 36 months
Secondary Scaffold pattern irregularities - All cohorts Scaffold pattern irregularities are defined when struts are found in locations incongruent with the scaffold pattern, this is measured post-scaffold deployment and at follow up. They are classified into 2 categories: 1) 2 struts overhanging each other in the same angular sector of the lumen perimeter, with or without malapposition; and/or 2) isolated struts located more or less at the center of the vessel without obvious connection to the expected adjacent strut pattern. Baseline
Secondary Scaffold pattern irregularities - Cohort A Scaffold pattern irregularities are defined when struts are found in locations incongruent with the scaffold pattern, this is measured post-scaffold deployment and at follow up. They are classified into 2 categories: 1) 2 struts overhanging each other in the same angular sector of the lumen perimeter, with or without malapposition; and/or 2) isolated struts located more or less at the center of the vessel without obvious connection to the expected adjacent strut pattern. 12 months
Secondary Scaffold pattern irregularities - Cohort B Scaffold pattern irregularities are defined when struts are found in locations incongruent with the scaffold pattern, this is measured post-scaffold deployment and at follow up. They are classified into 2 categories: 1) 2 struts overhanging each other in the same angular sector of the lumen perimeter, with or without malapposition; and/or 2) isolated struts located more or less at the center of the vessel without obvious connection to the expected adjacent strut pattern. 24 months
Secondary Scaffold pattern irregularities - Cohort C Scaffold pattern irregularities are defined when struts are found in locations incongruent with the scaffold pattern, this is measured post-scaffold deployment and at follow up. They are classified into 2 categories: 1) 2 struts overhanging each other in the same angular sector of the lumen perimeter, with or without malapposition; and/or 2) isolated struts located more or less at the center of the vessel without obvious connection to the expected adjacent strut pattern. 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04098172 - Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR N/A